This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Research-based Pharmaceutical Industry Launches 'Do You Mind?' Campaign To Fight Mental And Neurological Disorders

GENEVA, May 21, 2013 /PRNewswire/ --

 
  • Campaign launched during World Health Assembly, where world's health ministers gather to address the large physical and economic costs of these disorders
  • Mental and neurological disorders (MNDs) affect 700 million people annually and account for 30 percent of global non-communicable disease (NCD) burden
  • 'Do You Mind?' helps patients, family members, policymakers and others to understand the role each can play to collectively address MNDs

Today the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) launched the 'Do You Mind?' campaign to focus attention and to prompt action on MNDs. The campaign launch takes place at the start of the 66 th World Health Assembly, where health ministers meet to consider a global mental health action plan.

'Do You Mind?' leverages various profiles to help patients, physicians, employers, policymakers, and the general public understand the role each actor can play in collectively addressing MNDs. Also interactive questioning is used to highlight the impact of MNDs across society, reduce stigma, and dispel common myths.

The World Health Organization reports that 700 million cases of MNDs occur annually and that MNDs account for 30 percent of the global non-communicable disease (NCD) burden. MNDs include schizophrenia, epilepsy, Alzheimer's disease, and depression, which alone affects more than 350 million people. In addition to the personal toll, MNDs have a large socio-economic cost: 40 percent of lost worker productivity in OECD countries is attributable to MNDs. [1]

"More than just a health issue, MNDs should be a societal priority involving decision makers from education, employment, science, government and other spheres," said Eduardo Pisani, IFPMA Director General. "'Do You Mind?' brings these actors together by showing how everybody can act to collectively reduce suffering."

The campaign is publicly available and can be accessed at: http://www.DoYouMindCampaign.org

About the IFPMA:

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,776.91 +93.33 0.53%
S&P 500 2,081.34 +12.58 0.61%
NASDAQ 4,997.4590 +5.5190 0.11%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs